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Abstract
Large vessel vasculitis (LVV) is defined as a disease mainly affecting the large arteries, with two major variants, Takayasu arteritis
(TA) and giant cell arteritis (GCA). GCA often coexists with polymyalgia rheumatica (PMR) in the same patient, since both belong
to the same disease spectrum. FDG-PET/CT is a functional imaging technique which is an established tool in oncology, and has also
demonstrated a role in the field of inflammatory diseases. Functional FDG-PET combined with anatomical CT angiography, FDG-
PET/CT(A), may be of synergistic value for optimal diagnosis, monitoring of disease activity, and evaluating damage progression in
LVV. There are currently no guidelines regarding PET imaging acquisition for LVVand PMR, even though standardization is of the
utmost importance in order to facilitate clinical studies and for daily clinical practice. This work constitutes a joint procedural
recommendation on FDG-PET/CT(A) imaging in large vessel vasculitis (LVV) and PMR from the Cardiovascular and
Inflammation & Infection Committees of the European Association of Nuclear Medicine (EANM), the Cardiovascular Council
of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the PET Interest Group (PIG), and endorsed by the
American Society of Nuclear Cardiology (ASNC). The aim of this joint paper is to provide recommendations and statements, based
on the available evidence in the literature and consensus of experts in the field, for patient preparation, and FDG-PET/CT(A)
acquisition and interpretation for the diagnosis and follow-up of patients with suspected or diagnosed LVV and/or PMR. This
position paper aims to set an internationally accepted standard for FDG-PET/CT(A) imaging and reporting of LVVand PMR.
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Introduction
Large vessel vasculitis (LVV) is defined as a disease mainly
affecting the large arteries, with two major variants, Takayasu
arteritis (TA) and giant cell arteritis (GCA) [1]. Vasculitis can
be distributed locally in the branches of the internal and ex-
ternal carotid artery or the aorta and its main branches more
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centrally in the thorax. TA and GCA are different diseases with
different age of onset, ethnic distribution, immunogenic back-
ground [2], and distribution and therapy response [3, 4] of the
affected arteries. GCA and TA also show some overlap with
regard to the histopathology of arterial lesions, reflecting shared
pathways in tissue inflammation [5, 6]. Clinically, GCA and
polymyalgia rheumatica (PMR) belong to a disease spectrum,
and both often coexist in the same patient. Nearly half of pa-
tients with GCA have evidence of PMR, while approximately
20% of patients with PMR have concomitant GCA [7, 8], al-
though the frequency of GCA in PMR (either by biopsy or
imaging) may vary, depending on the cohort selection criteria.
FDG-PET/CT is a functional imaging technique which is an
established tool in oncology, and has also demonstrated a role in
the field of inflammatory diseases. FDG-PET is based on the
ability to detect enhanced glucose uptake from high glycolytic
activity of inflammatory cells in inflamed arterial walls and
synovia/bursa [9]. Thereby, it can identify the presence of sys-
temic LVV in patients with GCA and TA, and it can also show
inflammation of peri-articular and extra-articular synovial struc-
tures in the case of PMR. Approximately 20% of patients with
apparently isolated PMR show LVVon FDG-PET/CT [10], and
this percentage can be even higher, depending on the presence
of LVV symptoms [11–13]. It is important to realize that a
negative temporal artery biopsy, an ultrasonography without a
halo sign, or magnetic resonance imaging (MRI) without aortic
wall thickening or edema does not definitively exclude the pres-
ence of LVVand should therefore not limit the use of FDG-PET/
CT when LVV is clinically suspected [14, 15]. Furthermore,
there is substantial variation in the type of vessels involved
(i.e. aortic and cranial large vessels) [16], which can be detected
by FDG-PET, given its whole-body scan nature, with the excep-
tion of the temporal artery, due to the high physiological FDG
uptake in the brain and limited resolution of the camera system.
In addition, FDG-PET may assist in the differential diagnosis
between PMR and elderly-onset rheumatoid arthritis (EORA) or
spondyloarthritis [8], according to the location of inflammation
(articular, capsular, or extracapsular). In patients with fever of
unknown origin (FUO), when the diagnosis of systemic LVV is
ruled out, FDG-PET/CT results enable the identification of other
causes of the inflammatory process, including oncological dis-
eases, in the majority of cases. Functional FDG-PET combined
with anatomical CT angiography, FDG-PET/CT(A), may be of
synergistic value for optimal diagnosis, disease activity moni-
toring, and evaluation of damage progression in LVV [17]. The
main limitation of FDG-PET/CT(A) to becoming a standardized
diagnostic tool is the lack of an internationally accepted defini-
tion of vascular inflammation and/or PMR, based on the inten-
sity and pattern of the glucose analogue uptake. Also, FDG-
PET/CT is not disease specific and is primarily developed to
diagnose malignant and infectious/inflammatory diseases.
Results have to be interpreted with caution as inflammatory/
metabolic changes in the arterial wall usually precede
Preamble The Society of Nuclear Medicine and Molecular Imaging
(SNMMI) is an international scientific and professional organization
founded in 1954 to promote the science, technology, and practical appli-
cation of nuclear medicine. The European Association of Nuclear
Medicine (EANM) is a professional nonprofit medical association that
facilitates communication on a global basis between individuals pursuing
clinical and research excellence in nuclear medicine. The EANM was
founded in 1985. SNMMI and EANM members are physicians, technol-
ogists, and scientists specializing in the research and practice of nuclear
medicine.
The SNMMI and EANM will periodically define new guidelines for
nuclear medicine practice to help advance the science of nuclear medicine
and to improve the quality of care to patients throughout the world.
Existing practice guidelines are reviewed for revision or renewal, as ap-
propriate, on their fifth anniversary, or sooner if indicated.
Each practice guideline, representing a policy statement by the SNMMI/
EANM, has undergone a thorough consensus process in which it has been
subjected to extensive review. The SNMMI and EANM recognize that
the safe and effective use of diagnostic nuclear medicine imaging requires
specific training, skills, and techniques, as described in each document.
Reproduction or modification of the published practice guideline by en-
tities not providing these services is not authorized.
These guidelines are an educational tool designed to assist practitioners in
providing appropriate care for patients. They are not inflexible rules or
requirements of practice and are not intended, nor should they be used, to
establish a legal standard of care. For these reasons and those set forth
below, both the SNMMI and the EANM caution against the use of these
guidelines in litigation in which the clinical decisions of a practitioner are
called into question.
The ultimate judgment regarding the propriety of any specific procedure
or course of action must be made by the physician or medical physicist in
light of all the circumstances presented. Thus, there is no implication that
an approach differing from the guidelines, standing alone, is below the
standard of care. To the contrary, a conscientious practitioner may respon-
sibly adopt a course of action different from that set forth in the guidelines
when, in the reasonable judgment of the practitioner, such course of
action is indicated by the condition of the patient, limitations of available
resources, or advances in knowledge or technology subsequent to publi-
cation of the guidelines.
The practice of medicine includes both the art and the science of the preven-
tion, diagnosis, alleviation, and treatment of disease. The variety and com-
plexity of human conditions make it impossible to always reach the most
appropriate diagnosis or to predict with certainty a particular response to
treatment. Therefore, it should be recognized that adherence to these guide-
lines will not ensure an accurate diagnosis or a successful outcome. All that
should be expected is that the practitioner will follow a reasonable course of
action based on current knowledge, available resources, and the needs of the
patient, to deliver effective and safe medical care. The sole purpose of these
guidelines is to assist practitioners in achieving this objective.
This joint procedural recommendation paper on 2-[18F]-fluorodeoxyglucose
(FDG) positron emission tomography–computed tomography (PET/CT) or
PET/CT(A) (with angiography) imaging in large vessel vasculitis (LVV) and
polymyalgia rheumatica (PMR) has been developed under the auspices of
the Cardiovascular and Inflammation & Infection Committees of the
EANM, the Cardiovascular Council of the SNMMI, and the PET Interest
Group (PIG). The purpose of this paper is to assist imaging specialists and
clinicians in recommending, performing, and interpreting the results of
FDG-PET in patients with suspected LVVand PMR. In addition, the paper
highlights the importance of standardization and optimal procedural perfor-
mance of FDG-PET/CT(A) imaging in LVVand PMR, and emphasizes the
importance of bridging the gap between imaging specialists and clinicians
working in this field.
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anatomic changes [18–23]. Furthermore, whereas increased
FDG uptake is mainly seen in active disease processes, infor-
mation of advanced stages, for example calcification in chron-
ic or past inflammation, is mainly provided by morphological
imaging [24]. Atherosclerosis activity may also interfere with
the FDG-PET signal in patients with LVV [25]. Finally, the
instigating inflammatory process may have subsided, leaving
residual arterial stenosis or aortic aneurysms for which FDG-
PET is not the best imaging option.
In nuclear medicine, procedural guidelines for FDG-PET im-
aging have been published for both cancer [26] and infection/
inflammation [27]. However, LVVand PMR are distinct disease
entities, which require a specific technical approach. The inter-
pretation of FDG-PET images for LVV can be challenging, and
there is currently no consensus on how to interpret the images in
the setting of LVV. Furthermore, as previously described, FDG
uptake has been demonstrated to respond to glucocorticoids
(GC) therapy, which reduces metabolic cell activity. In this set-
ting, aortic/arterial wall thickening (visible on CTorMRI) is still
present due to a delayed morphological vascular response [28].
There are currently no guidelines regarding PET imaging
acquisition for LVVand PMR, even though standardization is
of the utmost importance for facilitating clinical studies and
for daily clinical practice.
The aim of this joint paper is to provide recommendations
and statements, based on the available evidence in the litera-
ture and consensus of experts in the field, for patient prepara-
tion and FDG-PET/CT(A) acquisition and interpretation in the
diagnosis and follow-up of patients with suspected or diag-
nosed LVV and/or PMR. This position paper aims to set an
internationally accepted standard for FDG-PET/CT(A) imag-
ing and reporting of LVV and PMR. An additional aim is to
facilitate prospective clinical studies and pooling of future
multi-center data. Other imaging modalities applied in LVV
diagnostics, such as MRI angiography and ultrasound, are
beyond the scope of this document.
FDG-PET/CT(A) procedures in LVV and PMR
Patient preparation and FDG-PET/CT(A) image
acquisition
Patient preparation
The main goal of adequate patient preparation is to reduce
physiologic tracer uptake in normal tissues (myocardium,
skeletal muscle, urinary tract and brown adipose tissue) while
maintaining uptake in diseased tissues and organs. Patients are
instructed to fast for at least 6 h prior to FDG administration
although intake of non-caloric beverages is allowed during
that period [27]. In addition, strenuous physical activities
should be avoided within 24 h before FDG administration.
At the moment of and after administration of FDG, patients
should relax in an adequately temperature-controlled room
(20–22 °C [68–71.6 °F]) to minimize physiologic uptake in
muscles and brown fat [29]. In some cases, FDG uptake in
brown fat can be reduced by beta-blocking drugs, e.g. orally
administered 20 mg propranolol 1 h before FDG injection
[30]. Prior to positioning on the table, patients are asked to
void urine. Patients with FUO and suspicion of cardiac in-
volvement (e.g. endocarditis, sarcoidosis) must prepare with
a special diet to reduce physiological myocardial uptake of
FDG. Patient preparation for cardiac FDG-PET imaging is
based on increasing the provision of fatty acids to the heart
and decreasing physiological uptake of glucose by the myocar-
dium. The SNMMI/ASNC/Society of Cardiovascular
Computed Tomography (SCCT) guidelines and SNMMI/
ASNC consensus document recommend preparation with a
fat-enriched diet lacking carbohydrates for 12–24 h prior to the
scan, a 12–18 h fast, and/or the use of intravenous unfractionated
heparin approximately 15 min prior to FDG injection [31, 32].
Serum glucose levels before FDG administration
Previous studies have shown that FDG uptake is reduced if
serum glucose levels exceed 7 mmol/L (126 mg/dL) [33–35],
thereby rapidly and efficiently shunting FDG to organs with a
high density of insulin receptors (e.g. skeletal and cardiac
muscles), resulting in altered FDG biodistribution and subop-
timal image quality [36].
The impact of glucose levels on FDG uptake in inflamma-
tory lesions is less well investigated. A study by Rabkin et al.
in 123 patients with suspected infection demonstrated that
hyperglycemia at the time of study had no significant impact
on the false-negative rate [33]. However, a prospective study
in 195 patients evaluating the impact of fasting glucose levels
on arterial uptake showed a negative correlation between up-
take in the arterial wall and pre-scan glucose levels, as well as
increased blood pool activity with increased glucose levels
[35]. In general, efforts should be made to reduce blood glu-
cose to the lowest possible level, but glucose levels below
7 mmol/L (126 mg/dL) are preferable.
Glucocorticoids and FDG administration
Glucocorticoids (GC) may reduce vascular wall uptake of
FDG; the available data regarding the effect of GCwithdrawal
on FDG uptake are scarce. Nielsen et al. recently confirmed
that diagnostic accuracy of LVV with FDG-PET remained for
3 days after initiation of GC, after which the signal decreased
significantly [37–39]. Thus there may be a diagnostic window
of opportunity within 3 days of initiation of GC.
A brief withdrawal of GC could Brestore^ pathological FDG
uptake and reduce the likelihood of a false-negative result, but
this is not known. At the same time, GC withdrawal may pose
1252 Eur J Nucl Med Mol Imaging (2018) 45:1250–1269
risks to the patient. In the case of GCA, especially if temporal
artery or ocular involvement is suspected, administration of GC
cannot be delayed or withdrawn due to possible ischemic com-
plications. In other conditions such as PMR or TA, withdrawing
or delaying therapy until after PET can be permitted unless there
is risk of ischemic complications (Table 1).
The use of GC may also increase FDG uptake in the liver,
resulting in underestimation and/or under-scoring of vascular
FDG uptake [40].
Acquisition time after FDG administration
A minimum of 60 min between intravenous FDG administra-
tion and acquisition has been recommended for adequate tracer
biodistribution [27]. Delayed acquisitions increase the vascular-
to-blood pool ratio, hence increasing contrast resolution [35],
and could make the measured vascular uptake more accurate
[41]. However, as the majority of LVV studies have been per-
formed at 60 min, PET-positive criteria at delayed time points
have not yet been evaluated in this setting andmay differ slight-
ly from those defined at the standard time interval. In contrast to
FDG-PET studies evaluating metabolic activity of atheroscle-
rotic lesions, studies comparing early (1 h) versus delayed (3 h)
imaging in LVVare scarce [42]. A small prospective study in 23
patients with suspicion of LVV concluded that delayed imaging
at 3 h yielded a more detailed image of the arterial wall, mainly
due to decreased blood pool activity [43]. The recently pub-
lished EANM position paper on the use of FDG-PET in ath-
erosclerosis recommends an interval of 2 h between FDG ad-
ministration and acquisition [44]. Currently, there is not enough
evidence to apply the same time window for LVV. At this time,
we recommend an uptake interval of at least 60 min.
Standardization of the time interval is essential, especially when
using semiquantitative analyses and when comparing FDG up-
take on follow-up studies and between institutes.
Patient positioning and acquisition parameters
There are currently no guidelines for image acquisition in LVV
or PMR, but whole-body acquisition from head to knee (op-
tionally including the feet) in the supine position with the arms
next to the body is recommended, because (PMR) patients are
generally unable to hold their arms above their head. For FDG-
PET/CT imaging, a low-dose non-contrast CT must be per-
formed for attenuation correction and anatomical localization.
Alternatively, a diagnostic contrast-enhanced CT may be per-
formed according to applicable local or national protocols and
guidelines. A contrast-enhanced CTA is useful for identifying
stenotic lesions in TA, but data are insufficient to support its
routine use for GCA LVV [45]. When using a contrast-
enhanced CTA, a low-dose CT scan should be performed prior
to intravenous contrast injection for attenuation correction and
subsequent standardized uptake value (SUV) calculations. The
impact of intravenous contrast agents on the accuracy of atten-
uation correction is considered acceptable only when CT data
are collected in the equilibrium or venous phase (i.e. delayed
acquisition), with the advantage of radiation dose reduction
[26]. Detection of smaller vascular structures in the head and
neck region can be improved by increasing the acquisition time
(~ doubled) per bed position to improve image quality, and
applying larger image matrices (thus smaller voxels) [46].
This will reduce the partial volume effect of smaller structures,
Table 1 Recommendations for
patient preparation and image
acquisition for FDG-PET/CT in
LVVand PMR
Parameter Recommendation
Dietary preparation Fast for at least 6 h prior to FDG administration
In the case of fever of unknown origin (FUO) or suspected
cardiac involvement:
Consider a fat-enriched diet lacking carbohydrates for 12–24 h
prior to the scan, a 12–18 h fast, and/or the use of intravenous
unfractionated heparin approximately 15 min prior to FDG injection
Blood glucose levels Preferably <7 mmol/L (126 mg/dL)
Glucocorticoids Withdraw or delay therapy until after PET, unless there is risk
of ischemic complications, as in the case of GCAwith temporal
artery involvement. FDG-PETwithin 3 days after start of GC is
optional as a possible alternative [37, 39]
Patient positioning Supine, arms next to the body
Scan range Head down to the feet
Scan duration 3D: 2–3 min/bed position*
Dose of FDG injection 3D: 2–3 MBq/kg (0.054–0.081 mCi/kg) body weight*
Incubation time after FDG injection Standard 60 min
PET/CT Low-dose non-contrast CT for attenuation correction
and anatomical reference
*Depending on vendor suggestion of camera system
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provided appropriate high-resolution image reconstruction set-
tings are chosen, e.g. minimal image filtering during recon-
struction and appropriate number of iterations/subsets to ensure
sufficient convergence and/or contrast recovery by the iterative
reconstruction process. When available, time-of-flight informa-
tion should be used during reconstruction.
Interpretation and reporting of FDG-PET/CT(A)
Interpretation criteria
Several factors may significantly influence the arterial wall FDG
uptake, andmust be taken into consideration for interpretation of
FDG-PET in LVVand PMR. For clinical routine, interpretation
criteria must be uniform, reproducible, and easy to use. Many
PET interpretation criteria have been proposed (Table 2), and
evidence from the last 15 years supports the use of a visual
grading scale (vascular to liver uptake) (Fig. 1). We propose
the use of a standardized 0-to-3 grading system as follows:
0 = no uptake (≤ mediastinum); 1 = low-grade uptake (< liver);
2 = intermediate-grade uptake (= liver), 3 = high-grade uptake
(> liver), with grade 2 possibly indicative and grade 3 considered
positive for active LVV (Table 3) [25, 73]. A total vascular
score (TVS) can be determined, for instance, at seven different
vascular regions (thoracic aorta, abdominal aorta, subclavian
arteries, axillary arteries, carotid arteries, iliac arteries, and
femoral arteries) as negative (0) or positive, further scored
semiquantitatively as 1 (minimal but not negligible FDG up-
take), 2 (clearly increased FDG uptake), or 3 (verymarked FDG
uptake). Therefore, a TVS could be calculated ranging from 0
(no vascular FDGuptake in any of the seven vascular regions) to
21 (vascular FDG uptake scored 3 in all seven territories).
As PMR and GCA frequently overlap, typical FDG joint
uptake patterns should be reported, including uptake in
glenohumeral synovia, subacromial-subdeltoid bursa,
supraspinatus tendinitis and biceps synovitis (shoulder),
trochanteric/ischial bursa, hip synovia, interspinous regions
of the cervical and lumbar vertebrae, or the synovial tissue
of the knees if present, including the use of a standardized 0-
to-3 grading system [74, 75] (Fig. 2).
Atherosclerotic vascular uptake [76, 77], frequent with ag-
ing, may be a source of false positivity for LVV evaluation,
despite a classical Bpatchy^ uptake pattern. Uptake in
iliofemoral arteries should be interpreted with caution, be-
cause this is a frequent site of atherosclerosis. Taking these
considerations into account, vascular inflammation in LVVon
FDG-PET classically appears as a smooth linear pattern, in-
volving the aorta and its main branches (subclavian, carotid or
vertebral arteries, pulmonary arteries specifically in TA), but
not all main branches have to be involved.
Quantification issues requiring further clarification Several
semiquantitative methods have also been proposed, from simple
SUV metrics to target-to-background ratios (TBR) (Table 2).
Table 2 Literature review of the
FDG-PET interpretation criteria
used in LVV
PET evaluation criteria References
Visual analysis
Giant cell arteritis / PMR Uptake pattern [7, 47]
Grading [19, 21, 48–58]
Total vascular score [59, 60]
Semiquantitative




Takayasu arteritis Visual analysis




Consensus recommendations (see supplement 1)
• Recommend patient fasting for at least 6 h prior to FDG administration,
although intake of non-caloric beverages is allowed during that period
(evidence level II, grade B).
• Normal blood glucose levels are desirable, but glucose levels below
7 mmol/L (126 mg/dL) are preferable (evidence level II, grade B).
• Withdraw or delay GC therapy until after PET, unless there is risk of
ischemic complications, as in the case of GCAwith temporal artery
involvement. FDG-PETwithin 3 days after start of GC is optional as a
possible alternative (evidence level III, grade B).
• A minimum interval of 60 min is recommended between FDG
administration and acquisition for adequate biodistribution (evidence
level III, grade B).
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The clinical utility of SUVor TBR for initial diagnosis of LVVor
PMR is currently unknown, and their use is not recommended.
However, their relevance for recurrence or follow-up evaluation
may be of interest. Simple SUV metrics do not appear relevant
in initial diagnosis, due to the high overlap between patients and
controls [62] and the potential loss of specificity [48]. TBR
methods using lung [12], liver [61], or blood pool [62, 70] as a
reference have been proposed, mainly in GCA studies. A target-
to-blood pool method was recently applied successfully in LVV,
was highly reproducible in atheroma [78], and is currently rec-
ommended by the cardiovascular committee of the EANM for
the assessment of vascular wall inflammation in this setting [44].
Based on the few promising results in LVV [40, 62], we encour-
age the use of this target-to-blood pool method in LVV for
research studies. The use of TBR instead of SUVis recommend-
ed, as the use of a ratio between two measurements limits the
effects on signal quantification of errors in patient weight,
injected radiotracer dose, and imaging time point [44].
The normalization of the arterial wall uptake to the back-
ground activity of venous blood pool provides a good refer-
ence for assessing vascular inflammation [40]. Also, grading
of arterial inflammation against the liver background is an
established method [25, 40].
Regions of interest (ROIs) are drawn around the majority
of the target arterial structure, while the chance of including
surrounding FDG uptake within the ROI needs to be mini-
mized [40]. For background quantification, the ROI is
projected on the right lobe of the liver to reduce the chance
of including the various veins and arteries running through the
liver. For blood pool, an ROI is drawn centrally in the blood
pool of the (inferior or superior) caval vein.
TBR varies as a function of blood pool activity, which can be
affected by many factors, including (1) FDG uptake in circulat-
ing blood cells, (2) chronic renal insufficiency, and (3) blood
glucose levels [79, 80]. A study by Lensen et al. in patients with
atherosclerosis showed that results were affected by several data
acquisition parameters, i.e. FDG uptake time and SUV normal-
ization [81]. Although the individual factors may not have a
large impact by themselves, the cumulative effects of these
factors may result in substantial differences in reported SUVs
throughout studies and within multi-center trials. Repeated
PET/CT examinations should be performed using the same
protocol as in the previous studies. Semiquantitative analysis
should be similarly performed (in order to compare PET/CT
results). For treatment response evaluation, it is important to
have basic (prior to therapy) PET/CT results, as the detection
of even slight FDG uptake in the region of the initial lesion
should be considered a residual inflammatory process.
Fig. 1 FDG-PET. Low (grade 1),
intermediate (grade 2), and high
(grade 3) LVV FDG uptake
patterns including SUVmax values
of the thoracic aorta in patients
with GCA. Ratio is defined as
average SUVmax of the thoracic
aorta divided by the liver region.
The total vascular score (TVS) is
the highest for the right-
positioned patient
Consensus recommendations
• We propose the use of a standardized grading
system: 0 = no uptake (≤ mediastinum); 1 = low-grade uptake
(< liver); 2 = intermediate-grade uptake (= liver), 3 = high-grade
uptake (> liver), with grade 2 considered possibly positive and
grade 3 positive for active LVV (evidence level II, grade B).
• Typical FDG joint uptake patterns including scapular and pelvic
girdles, interspinous regions of the cervical and lumbar vertebrae,
or the knees should be evaluated and reported if present (evidence
level II, grade B).
• Normalization of the arterial wall uptake to the background activity of
venous blood pool provides a good reference for assessing vascular
inflammation (evidence level II, grade B).
• Grading of arterial inflammation against the liver background is an
established method (evidence level II, grade B).
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Diagnostic accuracy of FDG-PET/CT(A) for LVV
and PMR
In general, the diagnostic performance of FDG-PET for
the detection of LVV is good; individual studies are sum-
marized in Table 4, and meta-analyses are summarized in
Table 5. A recent meta-analysis of eight studies including
170 LVV patients with GCA or TA and 230 controls
confirmed that FDG-PET offers good diagnostic perfor-
mance for the identification of LVV [86]. The diagnostic
performance of FDG-PET was higher for the detection of
GCA than TA (87% vs. 58%, respectively; p < 0.0001)
[73, 86], but was impaired in patients under GC and/or
immunosuppressive treatment at the time of imaging [73].
Of note, patients with TA are more often receiving long-
term treatment at the time of imaging than patients with
Table 3 Proposed standardized
FDG-PET/CT(A) interpretation
criteria in LVV
Recommended PET interpretation criteria
For clinical use LVV visual grading (GCA and TA)
Grade 0: No vascular uptake (≤ mediastinum)
Grade 1: Vascular uptake < liver uptake
Grade 2: Vascular uptake = liver uptake, may be PET-positive
Grade 3: Vascular uptake > liver uptake, considered PET-positive
PMR associated visual assessment (only GCA)
Grade 0: No uptake
Grade 1: Uptake < liver uptake
Grade 2: Uptake = liver uptake
Grade 3: Uptake > liver uptake
Increased metabolic activity of the scapular and pelvic girdles
Increased metabolic activity of the knee bursae and capsule
Increased metabolic activity at the site of the cervical and
lumbar interspinous bursae
Increased metabolic activity of the trochanteric and ischial bursae
In general for research only PET semiquantitative analysis*
Target: Average SUVmax artery of the vascular ROIs
Blood pool: Average SUVmean of several vein ROIs
TBR = average SUVmax artery / average SUVmean vein
Liver: SUVmax of a liver region, preferably the right lobe











Joints: scapulae and pelvic girdles, knees, cervical and
lumbar interspinous bursae, trochanteric and ischial bursae
For clinical use Contrast-enhanced (PET/)CTA
Regular vascular wall thickness (mm)
Contrast enhancement
Presence of stenosis / aneurysm
TBR target-to-background ratio; SUV standardized uptake value; ROI region of interest; TA Takayasu arteritis;
PMR polymyalgia rheumatica; GCA giant cell arteritis.
*SUV using EARL criteria [26]
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GCA. For the diagnosis of patients with GCA, FDG-PET
demonstrated high pooled sensitivity (90%) and specific-
ity (98%), without significant heterogeneity, in a meta-
analysis of four pooled studies including 57 patients with
giant cell arteritis and 176 controls [73]. These findings
are in line with a previous meta-analysis including GCA
patients evaluated by FDG-PET, showing pooled sensitiv-
ity and specificity of 80% and 89%, respectively [87]. In
TA, FDG-PET demonstrated pooled sensitivity of 87%
and specificity of 73% for the assessment of disease ac-
tivity in a recent meta-analysis of seven studies including
191 patients with TA, with significant heterogeneity [73].
These findings are in line with a previous meta-analysis
including TA patients evaluated by FDG-PET, showing
pooled sensitivity and specificity of 70% and 77%, re-
spectively [88]. The specificity of FDG-PET increased to
84% when considering studies using National Institutes of
Health (NIH) criteria [89] as the disease activity assess-
ment scale [73]. Visual analysis showed that high FDG
uptake correlated well with the presence of markers of
disease activity in TA, but vascular uptake was observed
in up to 67% of TA patients without markers of activity
[73].
The precise evaluation of diagnostic accuracy of FDG-PET
for the diagnosis of LVV faces several hurdles. First, in some
patients, FDG-PET represents the only modality that allows
for the diagnosis of LVV, and therefore cannot be compared to
a gold standard. For GCA, the diagnosis is usually classified
according to the American College of Rheumatology (ACR)
criteria [90], which include cranial symptoms, the presence of
an elevated erythrocyte sedimentation rate (ESR), and a pos-
itive superficial temporal artery biopsy (TAB). Arterial wall
inflammation in GCA, however, is characterized by a segmen-
tal distribution, and can be absent in the excised segment of
the superficial temporal artery. The presence of aortitis in pa-
tients with PMR is even more difficult to confirm, as FDG
uptake is most often the only modality that allows for the
detection of inflammatory activity in large vessels. The diag-
nosis of TA is usually based on the NIH score [89], which
integrates clinical, biological, and radiological criteria.
Several studies, however, have found that there might be dis-
crepancies between the activity of TA evaluated with the NIH
score and the results of FDG-PET imaging [73]. This raises
the question of whether FDG-PET is more sensitive than the
NIH score for detecting and assessing TA, or whether this
vascular signal has no relation with active progressive disease.
Second, patients with suspected GCA often immediately re-
ceive high-dose GC before imaging, which has an impact on
the intensity of arterial FDG uptake subsequently measured
with PET. The accuracy of FDG-PET can therefore vary in
relation to the delay between the initiation of GC therapy and
imaging. Third, the accuracy of a diagnostic test is influenced
by the criteria used to define the presence of the disease. To
date, there are no definitive consensus criteria for the presence
of vascular inflammation with FDG-PET in LVVor PMR. In
summary, based on the available evidence, FDG-PET imaging
has high diagnostic value for the detection of LVV or PMR.
Future studies are needed to select the most clinically relevant
and reproducible criteria for defining the presence of LVV
with FDG-PET, as well as to test the clinical impact of
Fig. 2 FDG-PET. Low (grade 1),
intermediate (grade 2), and high
(grade 3) FDG uptake patterns of
the large joint regions in PMR
patients, including SUVmax of the
shoulders. Ratio is defined as
average SUVmax in the shoulders
divided by the liver region. The
total number and intensity of
affected joints is the highest for
the right-positioned patient
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FDG-PET imaging on the management of patients with
suspected LVV.
CT angiography in LVV and PMR
Image acquisition
Little data has been published concerning the additional value
of CTA for the diagnosis of LVV. Such evaluation could be of
interest by providing morphological information on the vas-
culature in a Bone-stop shop^ procedure when using hybrid
PET/CTA imaging (Fig. 3). In acute disease stages, CTA can
focus on the vascular lumen for both the detection and char-
acterization of stenosis and the assessment of acute complica-
tions of a critical stenosis. In chronic disease stages, CTA is an
alternative to MRI for detecting late complications such as
aneurysm formation and is helpful in planning percutaneous
and surgical treatment. However, given the currently limited
evidence supporting the use of contrast-enhanced PET/CT in
LVV, further studies are necessary to assess its potential incre-
mental value.
CTA scanning parameters should be adapted to the specific
capabilities of the local scanner specifications (Table 6). In
2014, the Task Force for the Diagnosis and Treatment of
Aortic Diseases of the European Society of Cardiology
(ESC) produced guidelines for CTA in the diagnosis of aortic
disease in adults [91]. In 2016, the American College of
Radiology (ACR), the North American Society for
Cardiovascular Imaging (NASCI), the Society of
Interventional Radiology (SIR), and the Society for Pediatric
Radiology (SPR) jointly revised their guidelines for
performing body CTA [92]. These guidelines provide general
information regarding CTA scanning and image post-process-
ing, as specific scanning parameters and image reconstruction
settings differ substantially among CT vendors and machines.
Generally, these guidelines recommend, if available, the
use of a multi-detector-row CT (MSCT) scanner with wide
z-axis or volume coverage. The scans should be performed
with ECG triggering to avoid motion or pulsation artifacts of
the ascending aorta [93].
Contrast material is administered through a venous catheter
using an automated contrast material injector. The contrast
material dose depends on the patient's body weight, body





























































































































































































































































































































































































































































































• Based on the available evidence, FDG-PET imaging exhibits high di-
agnostic performance for the detection of LVVand PMR (evidence
level II, grade B).
• Further studies are needed to select the most clinically relevant and
reproducible criteria for defining the presence of LVV with FDG-PET,
as well as to test the clinical impact of FDG-PET imaging on the
management of patients with suspected LVV.
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CTA images should be reconstructed in thin slices (e.g. 1mm
thick) to allow for additional multiplanar reformation (MPR)
and 3D image post-processing. Preferably, isotropic voxels
should be achieved. Both filtered back-projection and iterative
reconstruction algorithms can be used, with the latter providing
improved image quality due to noise removal, and dose-saving
potential [94]. Medium-sharp or vascular reconstruction kernels
can be recommended with a reconstruction matrix of 512 × 512
pixels and angiographic window setting using a level of 100
Hounsfield units (HU) and width of 700 HU.
Interpretation and reporting
According to American College of Radiology guidelines, CTA
is indicated to Bdiagnose and localize diseases with primary
manifestations in the arterial wall, including vasculitis, infec-
tion, and degenerative disorders^ [92]. Arterial vessel wall
thickening is the typical sign of vascular inflammation on
contrast-enhanced CT images (Fig. 4). In vasculitis, mural
thickening usually involves the complete circumference of the
vessel wall, whereas in atherosclerosis, plaque formation starts
from a focal point rather than circumferentially. CTA-based
diagnosis is greatly facilitated in the absence of atherosclerotic
plaques and when the thickening is not concentric. A
circumferential aortic wall thickness of more than 2–3mmwith
adventitial and peri-adventitial contrast enhancement is sugges-
tive of aortitis [95, 96]. It is assumed that the degree of mural
contrast enhancement is associated with the inflammatory ac-
tivity, as studies have shown that aortic wall contrast enhance-
ment can resolve during GC therapy, while the wall thickening
may persist [39].
Diagnostic accuracy of CTA
Although CTA itself is helpful for diagnosing LVV, the diag-
nostic accuracy of combined FDG-PET/CTA scans remains
undefined. While the inflammatory activity within the vessel
wall is displayed with high sensitivity on FDG-PET images,
combining FDG-PET with CTA enhances specificity by pro-
viding high-resolution anatomical details.
CTA also helps to differentiate different pathologic FDG-
PET findings, as both vasculitis and atherosclerosis can demon-
strate increased FDG wall uptake. Equally important in the con-
tribution of CTA to the diagnostic accuracy of combined FDG-
PET/CTA is its role in detecting structural changes and potential
complications of vasculitis [96]. During the primary diagnostic
work-up, CTA often helps to identify or exclude acute or symp-
tomatic manifestations that require immediate therapy. For
Fig. 3 FDG-PET/CTA. On the left, a transaxial view of a contrast chest
CT in a 67-year-old man with GCA, with an enlarged diameter of the
ascending aorta of 41 × 41 mm and moderately increased wall thickness
of 3.1 mm, and severely increased wall thickness of 4.7 mm of the
descending aorta (diameter of 30 × 31 mm). On the right, the fused
transaxial images of the contrast chest CT and FDG-PET showing highly
elevated FDG uptake (average SUVmax 5.5) in the ascending and de-
scending aorta
Table 6 Recommendations for patient preparation and image acquisition for the CTA scan
Patient positioning Supine, arms next to the body for hybrid PET/CTA; otherwise, arms should be elevated.
Scan volume Entire aorta including the cervical, upper extremity, visceral and renal, pelvic, and proximal
lower extremity arterial branches
Contrast material administration 80 to 150 mL iodinated low-osmolar or iso-osmolar contrast material with concentrations
of 300 to 400 mg iodine per mL is injected at flow rates of 3.0–5.0 mL/s via antecubital vein.
Specific CTA settings Optimal arterial contrast phase:
Bolus tracking or test bolus technique, scanning in cranio-caudal direction
Avoidance of aortic motion artifacts:
ECG triggering
Specific CT machine settings Refer to individual CT scanner recommendations, as parameters and protocols may differ
among vendors and machines.
Eur J Nucl Med Mol Imaging (2018) 45:1250–1269 1261
example, inflammatory vascular stenosis can lead to serious
sequelae such as brain infarction or mesenteric ischemia with
bowel necrosis. Furthermore, initial CTA may provide informa-
tion on current disease stage, distribution, and duration. During
disease follow-up, CTA plays a particular role in the detection
and monitoring of complications such as aortic aneurysm and
dissection. While stenosis is frequently observed in TA, GCA
may lead to aortic or arterial dilatation. These dilated arteries may
enlarge to aneurysms during the disease course, even though
inflammatory activity is absent or sufficiently suppressed.
Monitoring the efficacy of immunosuppressive
therapy with FDG-PET/CT(A)
For monitoring of LVVactivity during and after treatment, re-
lated biomarker measurements would be helpful.
Unfortunately, both the cranial GCA and the extracranial large
vessel type of GCA or TA lack disease-specific serum
biomarkers.
Although FDG-PET/CT(A) has proven to be an important
imaging modality for diagnosis of non-temporal GCA, very
limited data are available on the role of FDG-PET/CT(A) for
patient management once treatment has started.With regard to
the utility of FDG-PET for assessing changes in arterial wall
inflammation in response to GC and methotrexate, the results
are mixed, and represent only small patient cohorts.
In the only prospective study, which was conducted by
Blockmans et al. (Table 7), whole-body FDG-PET/CT images
were acquired at baseline and after 3 and 6 months of GC
therapy [59]. The total vascular score (TVS) decreased from a
mean (± SD) of 7.9 ± 5.5 at baseline to 2.4 ± 3.5 on repeat
PET scan at 3 months (p < 0.0005), but no further decrease
was seen at 6 months. In patients who experienced a relapse
(recurrent signs and symptoms, together with an increase in
acute-phase reactants), FDG-PETwas performed within 5 days.
The authors found no difference in the predictive value of
FDG uptake between relapsing and non-relapsing patients.
A retrospective study by Bertagna et al. (Table 7) included
a total of nine patients, with eight GCA patients having a
normalized FDG-PET at follow-up after GC therapy, and
one patient without any change in the FDG-PET [97].
Fig. 4 CTangiography of the chest in two patients with GCA.Upper row
CTA of the aorta and the supra-aortic arteries in a 64-year-oldmale patient
with giant cell arteritis. Mural thickening and contrast enhancement of the
aortic wall (arrows in B). Please note hypodense inner ring delineating
luminal contrast-enhanced blood from contrast-enhancing thickened aor-
tic wall. Mural inflammatory changes are present in both subclavian
arteries as visualized in cross section (bold arrow in A) and in a
longitudinal section (light arrows in A). Asterisk in A indicates the left
subclavian vein. Lower rowAxial view of a CTangiography of a 76-year-
old woman with GCA showing severely increased wall thickness of
5.2 mm and contrast enhancement of the descending aorta (bold arrow)
(A). Contrast CT of the same patient performed 4 years earlier, with no
significant aortic wall thickening (B)
Consensus recommendation
• CTA and FDG-PET have complementary roles in the diagnosis of LVV
(evidence level III, grade B).
• CTA has incremental value in detecting structural vascular changes and
potential complications of vasculitis (evidence level II, grade A).
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Despite the small number of patients enrolled, the authors
concluded that FDG-PET/CT might be a useful and accurate
tool for evaluating disease progression.
In a study of five patients by Camellino et al. (Table 7),
FDG-PET uptake decreased after the addition of methotrexate
to the traditional GC treatment [99]. No studies have investi-
gated whether GCA disease activity can be monitored by
FDG-PET/CT in patients on GC-sparing drugs such as tumor
necrotic factor α (TNF-α) blocking agents for TA or
interleukin-6 receptor blockade (tocilizumab) for GCA
Interestingly, a recent abstract by Nielsen et al. [37] report-
ed that the FDG-PET/CT score, based on the semiquantitative
approach described by Meller et al. [55] (score < 3), remained
positive for vasculitis after 3 days of GC treatment, but be-
came negative after 10 days.
Recent studies have shown that at the temporal artery level,
granulomatous infiltrates can persist even up to 1 year follow-
ing the start of GC treatment [28, 101]. Macrophages and
granulomatous inflammation have been reduced with GC
treatment in experimental models [102], decreasing in a
time-dependent manner from 78 to 100% at initial biopsy, to
50% at 9 months and 25% at 12months in sequential temporal
artery biopsies. Lymphocytes may persist longer [102], and
have been reported to be present in GCA patients treated for
up to 1 year [28].
This is in agreement with a study by Brack et al., in which
macrophages persisted in the vessel walls of severe combined
immunodeficiency disorder (SCID) mice engrafted with TAB
after 1 week of GC treatment [103]. These findings are also in
line with the fact that FDG-PET/CT(A) shows arterial wall
uptake after 6 months in treated patients, although the uptake
is no longer diagnostic for vasculitis.
Prieto-González et al. prospectively assessed GC-induced
changes in CTA findings of LVV in patients with GCA [39].
Forty patients with biopsy-proven GCA evaluated by CTA at
diagnosis were prospectively followed and scheduled for a
new CTA after approximately 1 year of treatment. Vessel wall
thickening, diameter, and contrast enhancement of the aorta
and its tributaries were evaluated. Results were compared with
those obtained at the time of diagnosis. CTAwas repeated for
35 patients after a median follow-up of 13.5 months (IQ 25–
75% 12.4–15.8). Arterial wall thickening was still present in
17 patients (68% of the patients who initially had LVV). The
number of affected segments and the wall thickness at various
aortic segments were significantly decreased, and no patients
developed new lesions, new aortic dilation, or an increase in
previous dilation. Contrast enhancement disappeared in 15
(94%) of 16 patients in whom this finding could be assessed.
Signs of LVV improve with treatment. While contrast en-
hancement resolves in the majority of patients, vessel wall
thickening persists in two-thirds. However, the number of af-
fected aortic segments, as well as the aortic wall thickness,
decreases significantly.
For PMR, there is one study with sequential PET/CT,
by Blockmans et al. (Table 7), using the same methodol-
ogy as that for GCA. The authors found that vascular
FDG uptake was present in 11 patients, with slight or
moderate uptake at diagnosis in nine of 35 patients, and
that the uptake decreased after 3 and 6 months [60]. At
baseline, FDG uptake in the shoulders was present in all
but two patients, and uptake was still present, although to
a lesser extent, after 3 and 6 months of GC therapy. The
same holds true for the hips and the spinous processes.
No difference was found in the predictive value of FDG
uptake at baseline and after 3 months at the shoulders,
hips, or spinous processes between patients who experi-
enced a relapse and those who did not.
The optimal length of time before performing FDG-
PET in PMR after treatment with GC is unclear. A
recent study by Palard-Novello et al. evaluated the use of
FDG-PET/CT(A) for the assessment of tocilizumab as first-
line treatment in patients with PMR [104]. They found that
FDG uptake decreased significantly but moderately after toci-
lizumab therapy in PMR patients, and may reflect disease
activity.
Consensus statements on open issues
for future research agenda
Clinical issues
& Further establish the role of FDG-PET/CT in patient man-
agement and evaluate its role in treatment monitoring.
When to use FDG-PET/CT in the diagnosis, in the fol-
low-up, and how often?
& Development of guidelines in LVV and PMR imaging
with FDG-PET/CT(A) similar to those previously devel-
oped for FDG-PET/CT in oncology (EARL) criteria [26].
Randomized prospective studies are needed for more
evidence.
& Including imaging biomarkers with the current diag-
nostic criteria to be considered for TA, GCA, and/or
PMR.
& Finding a consensus in the clinical support for performing
imaging as early as possible and before starting GC ther-
apy if treatment delay can be justified due to non-critical
symptoms.
& Further investigation of the GC effect on vascular FDG
uptake.
Consensus statement
FDG-PET/CT(A) may be of value for evaluating response to treatment
by monitoring functional metabolic information and detecting
structural vascular changes (evidence level III, grade C), but
additional prospective FDG-PET/CT(A) studies are warranted.
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& Theranostics (diagnostics for selected therapy) for LVV/
PMR, which may open more paths to targeted therapy,
resulting in personal/precision medicine. Radiolabeled
tocilizumab or other monoclonal antibody PET tracers
are potential candidates for this.
& Circumstances of when there may be myocardial involve-
ment in patients with LVV should be further investigated
(additional myocardial perfusion imaging, CT coronary
calcium assessment, and CTangiography may be needed),
including the risk of cardiovascular events due to drug
therapy in LVV [105].
& Worldwide reimbursement for application of FDG-PET/
CT(A) in LVV/PMR is needed.
Methodological issues
& Standardization of visual scoring and (semi)quantification
in FDG-PET in LVVand PMR is essential for interpreta-
tion, for optimal comparison among centers, especially in
future multicenter trials.
& Decide how much thickening is mild, moderate, or severe
(not established in literature). Based on our expertise, we
think that ≥2 mm (up to 2.9) may be mild, ≥ 3 mm (up to
3.9) moderate, and ≥4 mm severe.
& Consensus needed on which quantification method to ap-
ply in LVV.
& An uptake interval of 60 min after FDG injection is rec-
ommended, but 90–120 min intervals can be evaluated for
better image quality.
& Dual-time-point imaging may improve the target-to-
background ratio, resulting in better image quality due to
greater FDG blood pool clearance, particularly in patients
with reduced kidney function. However, evidence-based
data are lacking.
& New techniques for imaging and reconstruction of the
skull that enable visualization of the superficial temporal
artery, which will result in better comparison of local LVV
with TAB.
& Value of combining FDG-PET with CTA as a standard
procedure in LVVand PMR, single modalities or hybrid.
& Value of FDG-PET/MRI in monitoring LVV and PMR,
i.e. reduction of radiation dose [106].
& Development of online trainingmodalities for interpretation.
Technical issues
& Optimization of the application of hybrid imaging in mon-
itoring (residual) vascular wall disease in LVV.
& The use of vasculitis-specific tracers, directed against
cells/proteins involved in and unique for the pathophysi-
ology of LVVand PMR, should be investigated.
& New developments in camera systems, such as PET/MRI,
enable us to combine metabolism or other molecular targets
(PET) with vascular tissue layer characterization (MRI),
including a reduction in radiation dose and improved cra-
nial visualization. The value of these new multi-modality
imaging systemsmay be of interest for LVVassessment and
monitoring.
& Optimal use of (low-dose) CT to distinguish active athero-
sclerosis from active vasculitis by pattern recognition, vi-
sually as well as with the use of dedicated software meth-
odologies (textural feature).
Several open issues are also in line with the recommendation
for the use of imaging in large vessel vasculitis in clinical practice
of the European League Against Rheumatism (EULAR) [107].
Conclusion
The present procedural recommendation paper provides rec-
ommendations to assist imaging specialists and clinicians in
requesting, performing, and interpreting the results of FDG-
PET in patients with suspected LVVand PMR.
Based on the present clinical data, FDG-PET/CT(A) has an
important role in the diagnosis of extracranial vascular in-
volvement in patients with LVV/PMR, but additional random-
ized studies are needed to support this.
Improvements in FDG-PET/CT(A) procedures will help to
optimize the diagnostic andmonitoring value of this technique
in LVV/PMR.
Visual qualitative methods are most commonly used, but
semiquantitative methods such as the vascular/blood ratio and
vascular/liver ratio using SUVs are increasingly being used.
The addition of CTA to FDG-PET provides high-resolution
imaging of vascular morphology that can potentially improve
diagnostic accuracy, but more importantly provides informa-
tion on the presence of possible complications such as steno-
sis, organ ischemia, aneurysm formation, and dissection.
Further prospective studies involving large cohorts of GCA/
PMR patients are needed to investigate and validate the role of
semiquantitative methods for the assessment of LVV.
Several other open issues, as stated above, need to be stud-
ied for optimal performance of FDG-PET/CT(A) in the diag-
nosis, (treatment) monitoring, and future theranostics in LVV/
PMR, further improving the levels of evidence and grades of
recommendations.
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